No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
253 |
4. Check minimum number of eventsNone |
253 |
5. Include endpointsNone |
253 |
6. Filter based on genotype QC (FinnGen only) |
239 |
Control definitions (FinnGen only)
- Control exclude
- Q17_OTHER_CONGEN_MALFO
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Neurofibromatosis, type 1
based on the number of shared cases.
Similar with more cases:
- Phakomatoses, not elsewhere classified
- Other congenital malformations
- Other congenital malformations, including avohilmo
- Congenital malformations, deformations and chromosomal abnormalities
- Congenital malformations, deformations and chromosomal abnormalities, including avohilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 239 | 145 | 94 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.04 |
| Median age at first event (years) | 37.30 | 36.96 | 37.83 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 253
- Matched controls
- 2530
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q85.00
ICD-10 Finland
Neurofibromatosis, type 1
+∞
307.7
253
*
Q85.09
ICD-10 Finland
Unspecified neurofibromatosis
+∞
151.8
130
*
Z31.5
ICD-10 Finland
Genetic counselling
21.7
125.2
114
92
Q85.0
ICD-10 Finland
Neurofibromatosis (nonmalignant)
+∞
97.3
87
*
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
15.8
78.0
77
68
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
12.4
54.1
60
62
2377A
ICD-9 Finland
Neoplasm of uncertain behaviour of endocrine glands and nervous system, Neurofibromatosis
+∞
53.0
49
*
Q85.01
ICD-10 Finland
Neurofibromatosis, type 2
+∞
48.5
45
*
QDE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in lower limb
16.7
46.1
41
29
74340
ICD-8 Finland
Other congenital anomalies of nervous system, Neurofibromatosis
+∞
38.5
36
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.6
37.0
72
143
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.1
33.9
99
281
XCK00
NOMESCO Finland
Perimetry
9.0
31.1
42
55
Q85.1
ICD-10 Finland
Tuberous sclerosis
+∞
30.9
29
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
9.3
25.9
33
40
Q85.9
ICD-10 Finland
Phakomatosis, unspecified
+∞
24.4
23
*
QCE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in upper limb
17.7
19.4
30
19
NDR20
NOMESCO Finland
Incomplete excision of soft tissue tumour of wrist or hand
27.6
18.6
25
10
TQW99
NOMESCO Finland
Other minor procedure on skin
6.6
16.4
28
47
ACB19
NOMESCO Finland
Excision of lesion of peripheral nerve other or unspecified
51.1
16.3
19
*
D36.1
ICD-10 Finland
Benign neoplasm: Peripheral nerves and autonomic nervous system
90.8
15.8
17
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.9
15.1
36
83
ZXC10
NOMESCO Finland
Use of laser
12.5
14.7
26
23
R4120
NOMESCO Finland
Occupational therapy
4.7
14.4
36
86
QBA25
NOMESCO Finland
Destruction of lesion of skin of trunk
19.6
13.6
20
11
D33.30
ICD-10 Finland
Acoustic neuroma
28.3
12.2
16
6
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
4.9
11.7
27
60
XCK10
NOMESCO Finland
Photography of fundus of eye
3.9
11.0
35
100
QDA25
NOMESCO Finland
Destruction of lesion of skin of lower limb
114.6
10.5
11
*
L81.3
ICD-10 Finland
Café au lait spots
+∞
10.5
10
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
24.6
10.4
14
6
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.2
10.3
46
165
NK1AT
NOMESCO Finland
Muscle biopsy with ultrasound guidance
57.2
9.7
11
*
D48.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Neoplasm of uncertain or unknown behaviour, unspecified
10.7
9.7
18
18
Q82.50
ICD-10 Finland
Naevus flammeus
103.8
9.5
10
*
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
9.1
9.0
18
21
XCW99
NOMESCO Finland
Other investigative procedure of eye
3.4
8.8
34
111
WX408
NOMESCO Finland
General anesthesy, balanced
2.4
8.7
81
420
ZXE10
NOMESCO Finland
More than one and less than three hours
2.3
8.6
98
553
9736
FHL
Subcutaneous tumor removal in operating room or anesthesia
20.9
8.6
12
6
ZXE30
NOMESCO Finland
More than five and less than seven hours
4.7
8.5
20
45
ZXA00
NOMESCO Finland
Right side
2.5
8.5
67
322
ZXC07
NOMESCO Finland
Carbon dioxide laser
93.0
8.5
9
*
QBA40
NOMESCO Finland
Laser therapy or photocoagulation of skin of trunk
93.0
8.5
9
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
10.0
8.4
16
17
QXA40
NOMESCO Finland
Skin laser treatment or photocoagulation, unspecified location
+∞
8.4
8
*
XA800
NOMESCO Finland
Neuropsychological investigation
3.9
8.4
26
73
SPAT1229
SPAT
Assessment of need for aid
4.8
8.3
19
42
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
10.5
8.1
15
15
D37.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Small intestine
34.6
8.1
10
*
ZXD10
NOMESCO Finland
Scheduled procedure
2.2
8.0
102
599
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
8.0
45
183
D33.45
ICD-10 Finland
Benign Schwannom in the nerve root of the spinal cord
46.4
7.8
9
*
NFR20
NOMESCO Finland
Incomplete excision of soft tissue tumour of hip or thigh
46.4
7.8
9
*
D21.1
ICD-10 Finland
Benign neoplasm: Connective and other soft tissue of upper limb, including shoulder
19.1
7.7
11
6
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
9.3
7.7
15
17
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
9.3
7.7
15
17
D48.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Connective and other soft tissue
8.1
7.5
16
21
WX1DG
NOMESCO Finland
Very extensive total body MRI with high intensity magnet
+∞
7.3
7
*
C72.3
ICD-10 Finland
Malignant neoplasm: Optic nerve
+∞
7.3
7
*
QAE40
NOMESCO Finland
Repair of anomaly or lesion after disease of skin of head or neck
+∞
7.3
7
*
D33.46
ICD-10 Finland
Benign neurofibroma in the nerve root of the spinal cord
+∞
7.3
7
*
SPAT1153
SPAT
Removal of sutures
2.2
7.3
80
440
TPH07
NOMESCO Finland
Cathetrisation of artery
3.0
7.2
33
119
H47.2
ICD-10 Finland
Optic atrophy
31.0
7.2
9
*
QA4S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in face
31.0
7.2
9
*
WX002
NOMESCO Finland
Sedation and analgesia
2.5
7.2
51
232
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
9.2
7.1
14
16
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
7.3
7.1
16
23
Z01.1
ICD-10 Finland
Examination of ears and hearing
2.6
7.0
44
189
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
7.5
6.8
15
21
QAA25
NOMESCO Finland
Destruction of lesion of head or neck
8.2
6.7
14
18
N03AF02
ATC
oxcarbazepine; oral
4.4
6.7
17
41
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
12.7
6.6
11
9
L28
ICPC
Limited function/disability (L)
2.5
6.6
45
200
D23.5
ICD-10 Finland
Benign neoplasm: Skin of trunk
6.0
6.6
17
30
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
7.7
6.5
14
19
ZXE20
NOMESCO Finland
More than three and less than five hours
2.6
6.5
40
170
NA1DG
NOMESCO Finland
Cervical spine very extensive MRI examination with high intensity magnet
71.6
6.5
7
*
QCA40
NOMESCO Finland
Laser therapy or photocoagulation of skin of upper limb
71.6
6.5
7
*
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.5
6.5
23
71
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
14.8
6.4
10
7
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
18.6
6.3
9
5
QCA25
NOMESCO Finland
Destruction of lesion of skin of upper limb
18.6
6.3
9
5
WX1CG
NOMESCO Finland
Extensive total body MRI with high intensity magnet
+∞
6.3
6
*
N03AX14
ATC
levetiracetam; systemic
5.8
6.1
16
29
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Outpatient Visit
OP [9202]
OP [9202]
4.6e-01
1.1e+00
1.0e+00
6.4e+00
1.5e+00
1.8e+00
2.1e+00
cases:64.85%
controls:53.71%
cases:63.75%
controls:36.65%
cases:21.25%
controls:9.03%
cases:72.50%
controls:0.42%
cases:28.33%
controls:8.40%
cases:77.73%
controls:36.68%
cases:94.25%
controls:65.87%
155
1274
84
1098
153
873
87
1509
51
215
189
2167
174
10
66
2372
68
200
172
2180
185
867
53
1497
213
1494
13
774
Neurology
13 [38004458]
13 [38004458]
1.1e+00
1.7e+00
2.7e+00
1.0e+50
2.5e+00
2.5e+00
2.1e+00
cases:13.81%
controls:5.23%
cases:9.58%
controls:1.97%
cases:2.92%
controls:0.21%
cases:20.42%
controls:0.00%
cases:4.58%
controls:0.38%
cases:23.11%
controls:2.41%
cases:34.51%
controls:6.22%
33
124
206
2248
23
47
217
2335
7
5
233
2377
49
0
191
2382
11
9
229
2371
55
57
183
2307
78
141
148
2127
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
6.6e-01
2.3e+00
2.6e+00
1.0e+50
3.0e+00
2.2e+00
1.9e+00
cases:8.79%
controls:4.76%
cases:13.33%
controls:1.47%
cases:3.33%
controls:0.25%
cases:15.00%
controls:0.00%
cases:4.17%
controls:0.21%
cases:17.23%
controls:2.28%
cases:26.55%
controls:4.94%
21
113
218
2259
32
35
208
2347
8
6
232
2376
36
0
204
2382
10
5
230
2375
41
54
197
2310
60
112
166
2156
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
2.1e+00
2.7e+00
—
1.0e+50
1.0e+50
4.0e+00
2.7e+00
cases:7.95%
controls:1.10%
cases:5.83%
controls:0.42%
—
—
cases:8.75%
controls:0.00%
cases:2.50%
controls:0.00%
cases:12.61%
controls:0.25%
cases:22.12%
controls:1.81%
19
26
220
2346
14
10
226
2372
—
21
0
219
2382
6
0
234
2380
30
6
208
2358
50
41
176
2227
Neurosurgery
14 [38004459]
14 [38004459]
1.6e+00
2.6e+00
—
1.0e+50
—
2.5e+00
2.0e+00
cases:5.86%
controls:1.22%
cases:6.67%
controls:0.50%
—
—
cases:6.25%
controls:0.00%
—
—
cases:9.66%
controls:0.85%
cases:14.60%
controls:2.16%
14
29
225
2343
16
12
224
2370
—
15
0
225
2382
—
23
20
215
2344
33
49
193
2219
Paediatric neurology
421 [44777781]
421 [44777781]
1.7e+00
1.7e+00
—
—
—
2.3e+00
2.4e+00
cases:5.86%
controls:1.14%
cases:5.00%
controls:0.92%
—
—
—
—
—
—
cases:8.40%
controls:0.93%
cases:12.39%
controls:1.32%
14
27
225
2345
12
22
228
2360
—
—
—
20
22
218
2342
28
30
198
2238
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
OMOP4822000 [32411]
1.6e+00
2.7e+00
—
1.0e+50
—
—
3.1e+00
cases:4.18%
controls:0.84%
cases:6.67%
controls:0.46%
—
—
cases:9.17%
controls:0.00%
—
—
—
—
cases:14.16%
controls:0.71%
10
20
229
2352
16
11
224
2371
—
22
0
218
2382
—
—
32
16
194
2252
Genetic counselling
Z31.5 [45590715]
Z31.5 [45590715]
1.4e+00
2.7e+00
—
1.0e+50
—
—
3.1e+00
cases:2.51%
controls:0.63%
cases:5.42%
controls:0.38%
—
—
cases:4.58%
controls:0.00%
—
—
—
—
cases:9.73%
controls:0.49%
6
15
233
2357
13
9
227
2373
—
11
0
229
2382
—
—
22
11
204
2257
Excision of other lesion extending through all layers of skin of trunk
QBE10 [2001309853]
QBE10 [2001309853]
2.6e+00
—
—
1.0e+50
—
—
3.1e+00
cases:3.77%
controls:0.30%
—
—
—
—
cases:2.08%
controls:0.00%
—
—
—
—
cases:7.08%
controls:0.35%
9
7
230
2365
—
—
5
0
235
2382
—
—
16
8
210
2260
Ophthalmology
18 [38004463]
18 [38004463]
4.7e-01
8.9e-01
9.2e-01
1.0e+50
1.7e+00
1.8e+00
1.1e+00
cases:15.06%
controls:9.99%
cases:12.92%
controls:5.75%
cases:2.50%
controls:1.01%
cases:7.08%
controls:0.00%
cases:4.17%
controls:0.76%
cases:27.73%
controls:5.88%
cases:32.74%
controls:13.98%
36
237
203
2135
31
137
209
2245
6
24
234
2358
17
0
223
2382
10
18
230
2362
66
139
172
2225
74
317
152
1951
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
5.7e-01
1.3e+00
—
1.0e+50
—
1.8e+00
1.6e+00
cases:7.95%
controls:4.64%
cases:5.83%
controls:1.64%
—
—
cases:3.75%
controls:0.00%
—
—
cases:7.56%
controls:1.31%
cases:18.58%
controls:4.28%
19
110
220
2262
14
39
226
2343
—
9
0
231
2382
—
18
31
220
2333
42
97
184
2171
Examination of eyes and vision
Z01.0 [45566391]
Z01.0 [45566391]
2.4e-01
1.5e+00
—
—
—
1.7e+00
1.4e+00
cases:2.51%
controls:1.98%
cases:3.75%
controls:0.84%
—
—
—
—
—
—
cases:6.30%
controls:1.23%
cases:9.73%
controls:2.65%
6
47
233
2325
9
20
231
2362
—
—
—
15
29
223
2335
22
60
204
2208
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
-1.5e-01
6.9e-01
-1.0e+50
—
2.2e+00
1.1e+00
1.2e+00
cases:7.11%
controls:8.18%
cases:6.67%
controls:3.44%
cases:0.00%
controls:0.55%
—
—
cases:2.50%
controls:0.29%
cases:9.66%
controls:3.30%
cases:25.22%
controls:8.99%
17
194
222
2178
16
82
224
2300
0
13
240
2369
—
6
7
234
2373
23
78
215
2286
57
204
169
2064
oxcarbazepine; oral
N03AF02 [21604418]
N03AF02 [21604418]
—
2.0e+00
—
—
—
2.0e+00
2.2e+00
—
—
cases:2.08%
controls:0.29%
—
—
—
—
—
—
cases:2.52%
controls:0.34%
cases:4.42%
controls:0.53%
—
5
7
235
2375
—
—
—
6
8
232
2356
10
12
216
2256
General Surgery
2 [38004447]
2 [38004447]
2.8e-01
5.1e-01
—
1.0e+50
2.3e+00
1.0e+00
6.3e-01
cases:20.92%
controls:16.65%
cases:9.58%
controls:5.96%
—
—
cases:6.67%
controls:0.00%
cases:4.17%
controls:0.42%
cases:13.45%
controls:5.25%
cases:25.22%
controls:15.26%
50
395
189
1977
23
142
217
2240
—
16
0
224
2382
10
10
230
2370
32
124
206
2240
57
346
169
1922
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
5.8e-01
8.8e-01
—
1.0e+50
—
1.9e+00
1.6e+00
cases:5.02%
controls:2.87%
cases:2.50%
controls:1.05%
—
—
cases:2.08%
controls:0.00%
—
—
cases:4.20%
controls:0.68%
cases:10.18%
controls:2.34%
12
68
227
2304
6
25
234
2357
—
5
0
235
2382
—
10
16
228
2348
23
53
203
2215
Inpatient Hospital
21 [8717]
21 [8717]
2.3e-01
5.4e-01
1.0e+00
—
1.5e+00
1.2e+00
7.3e-01
cases:37.66%
controls:32.50%
cases:16.67%
controls:10.41%
cases:2.92%
controls:1.09%
—
—
cases:4.58%
controls:1.09%
cases:24.37%
controls:9.14%
cases:42.48%
controls:26.28%
90
771
149
1601
40
248
200
2134
7
26
233
2356
—
11
26
229
2354
58
216
180
2148
96
596
130
1672
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
7.7e-01
—
—
—
—
1.6e+00
1.6e+00
cases:4.18%
controls:1.98%
—
—
—
—
—
—
—
—
cases:3.78%
controls:0.80%
cases:10.18%
controls:2.25%
10
47
229
2325
—
—
—
—
9
19
229
2345
23
51
203
2217
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
6.0e-01
1.1e+00
—
1.0e+50
—
1.6e+00
1.5e+00
cases:6.28%
controls:3.54%
cases:3.33%
controls:1.13%
—
—
cases:2.92%
controls:0.00%
—
—
cases:5.88%
controls:1.23%
cases:16.37%
controls:4.01%
15
84
224
2288
8
27
232
2355
—
7
0
233
2382
—
14
29
224
2335
37
91
189
2177
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
QAE10 [2001309784]
1.5e+00
—
—
—
—
—
3.1e+00
cases:2.09%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:7.08%
controls:0.35%
5
11
234
2361
—
—
—
—
—
16
8
210
2260
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
1.6e-01
—
—
—
—
1.5e+00
1.3e+00
cases:2.51%
controls:2.15%
—
—
—
—
—
—
—
—
cases:3.78%
controls:0.85%
cases:9.29%
controls:2.73%
6
51
233
2321
—
—
—
—
9
20
229
2344
21
62
205
2206
Hand Surgery
40 [38004480]
40 [38004480]
3.3e-01
—
—
—
—
1.6e+00
1.2e+00
cases:2.09%
controls:1.52%
—
—
—
—
—
—
—
—
cases:3.36%
controls:0.68%
cases:7.08%
controls:2.29%
5
36
234
2336
—
—
—
—
8
16
230
2348
16
52
210
2216
Outpatient Hospital
22 [8756]
22 [8756]
5.3e-01
5.3e-01
—
—
—
1.3e+00
9.7e-01
cases:30.96%
controls:20.91%
cases:12.08%
controls:7.51%
—
—
—
—
—
—
cases:18.91%
controls:5.96%
cases:38.05%
controls:18.83%
74
496
165
1876
29
179
211
2203
—
—
—
45
141
193
2223
86
427
140
1841
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
AA1CG [2001300116]
—
2.0e+00
—
—
—
—
2.8e+00
—
—
cases:2.08%
controls:0.29%
—
—
—
—
—
—
—
—
cases:7.96%
controls:0.53%
—
5
7
235
2375
—
—
—
—
18
12
208
2256
Perimetry
XCK00 [2001301380]
XCK00 [2001301380]
—
2.3e+00
—
—
—
—
2.7e+00
—
—
cases:2.08%
controls:0.21%
—
—
—
—
—
—
—
—
cases:7.08%
controls:0.49%
—
5
5
235
2377
—
—
—
—
16
11
210
2257
Immunohistochemistry procedure
117617002 [4035726]
117617002 [4035726]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.10%
controls:0.22%
—
—
—
—
—
—
7
5
219
2263
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
2.9e-01
1.3e+00
—
—
—
9.3e-01
1.2e+00
cases:5.02%
controls:3.79%
cases:5.42%
controls:1.47%
—
—
—
—
—
—
cases:3.36%
controls:1.35%
cases:15.49%
controls:5.38%
12
90
227
2282
13
35
227
2347
—
—
—
8
32
230
2332
35
122
191
2146
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
A04AA01 [21600493]
-1.0e+50
—
—
—
—
—
2.5e+00
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:2.65%
controls:0.22%
0
7
239
2365
—
—
—
—
—
6
5
220
2263
Neuropsychological investigation
XA800 [2001300412]
XA800 [2001300412]
-1.0e+50
—
—
—
—
—
2.5e+00
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:3.54%
controls:0.31%
0
7
239
2365
—
—
—
—
—
8
7
218
2261
Occupational therapy
R4120 [2001310234]
R4120 [2001310234]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.54%
controls:0.31%
—
—
—
—
—
—
8
7
218
2261
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
TQX10 [2001310152]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.98%
controls:0.35%
—
—
—
—
—
—
9
8
217
2260
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
-9.3e-03
-3.6e-02
-3.2e-01
2.4e+00
3.6e-01
1.0e-01
8.7e-02
cases:32.64%
controls:32.84%
cases:26.67%
controls:27.37%
cases:7.50%
controls:10.08%
cases:9.17%
controls:0.88%
cases:13.33%
controls:9.66%
cases:31.93%
controls:29.70%
cases:53.10%
controls:50.93%
78
779
161
1593
64
652
176
1730
18
240
222
2142
22
21
218
2361
32
230
208
2150
76
702
162
1662
120
1155
106
1113
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
OMOP4822009 [45756830]
-1.0e+50
—
—
—
—
—
2.3e+00
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:3.10%
controls:0.31%
0
7
239
2365
—
—
—
—
—
7
7
219
2261
Complex partial epileptic seizure with secondary generalization
G40.22 [2000502141]
G40.22 [2000502141]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.65%
controls:0.26%
—
—
—
—
—
—
6
6
220
2262
Left side
ZXA05 [2001311347]
ZXA05 [2001311347]
8.4e-01
—
—
—
—
2.2e+00
9.5e-01
cases:4.18%
controls:1.85%
—
—
—
—
—
—
—
—
cases:3.78%
controls:0.42%
cases:5.31%
controls:2.12%
10
44
229
2328
—
—
—
—
9
10
229
2354
12
48
214
2220
Otolaryngology
4 [38004449]
4 [38004449]
4.0e-01
7.8e-01
-1.0e+50
1.0e+50
1.8e+00
1.2e+00
1.0e+00
cases:15.06%
controls:10.58%
cases:7.92%
controls:3.78%
cases:0.00%
controls:0.50%
cases:2.50%
controls:0.00%
cases:2.50%
controls:0.42%
cases:10.08%
controls:3.30%
cases:21.24%
controls:8.77%
36
251
203
2121
19
90
221
2292
0
12
240
2370
6
0
234
2382
6
10
234
2370
24
78
214
2286
48
199
178
2069
alendronic acid; oral
M05BA04 [21604152]
M05BA04 [21604152]
2.0e+00
—
—
—
—
—
2.2e+00
cases:2.09%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:4.87%
controls:0.57%
5
7
234
2365
—
—
—
—
—
11
13
215
2255
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
6.3e-02
5.6e-02
7.9e-02
2.2e+00
3.3e-01
2.3e-01
9.3e-03
cases:13.81%
controls:13.07%
cases:13.75%
controls:13.10%
cases:4.17%
controls:3.86%
cases:2.50%
controls:0.29%
cases:5.42%
controls:3.95%
cases:17.65%
controls:14.55%
cases:28.76%
controls:28.57%
33
310
206
2062
33
312
207
2070
10
92
230
2290
6
7
234
2375
13
94
227
2286
42
344
196
2020
65
648
161
1620
Pulmonary Disease
29 [38004472]
29 [38004472]
2.3e-01
1.0e+00
—
—
2.2e+00
8.4e-01
4.9e-01
cases:5.02%
controls:4.05%
cases:5.83%
controls:2.23%
—
—
—
—
cases:2.50%
controls:0.29%
cases:5.04%
controls:2.24%
cases:7.96%
controls:5.03%
12
96
227
2276
14
53
226
2329
—
—
6
7
234
2373
12
53
226
2311
18
114
208
2154
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
—
—
—
—
—
2.0e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:2.10%
controls:0.30%
cases:5.75%
controls:0.71%
—
—
—
—
—
5
7
233
2357
13
16
213
2252
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
47598-8 [3048816]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.10%
controls:0.44%
—
—
—
—
—
—
7
10
219
2258
Extensive body CT
JN4BD [2001310899]
JN4BD [2001310899]
—
—
—
—
—
-1.0e+50
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:3.54%
controls:0.53%
—
—
—
—
—
0
5
238
2359
8
12
218
2256
Functional capacity evaluation
443351003 [40481051]
443351003 [40481051]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.10%
controls:0.53%
—
—
—
—
—
—
7
12
219
2256
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
R5110 [2001310246]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.10%
controls:0.53%
—
—
—
—
—
—
7
12
219
2256
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
2.5e-01
1.6e-01
7.8e-01
—
1.8e+00
3.1e-01
4.2e-01
cases:31.38%
controls:26.22%
cases:10.83%
controls:9.36%
cases:2.08%
controls:0.97%
—
—
cases:5.42%
controls:0.97%
cases:11.34%
controls:8.59%
cases:37.17%
controls:28.09%
75
622
164
1750
26
223
214
2159
5
23
235
2359
—
13
23
227
2357
27
203
211
2161
84
637
142
1631
Examination of ears and hearing
Z01.1 [45547279]
Z01.1 [45547279]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.87%
controls:0.93%
—
—
—
—
—
—
11
21
215
2247
Limited function/disability (L)
L28 [2002000647]
L28 [2002000647]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.42%
controls:0.88%
—
—
—
—
—
—
10
20
216
2248
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
—
2.1e+00
—
—
—
—
1.6e+00
—
—
cases:2.08%
controls:0.25%
—
—
—
—
—
—
—
—
cases:3.98%
controls:0.79%
—
5
6
235
2376
—
—
—
—
9
18
217
2250
Pathology report gross observation
24419-4 [3002256]
24419-4 [3002256]
—
-1.0e+50
—
—
—
—
1.6e+00
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
cases:3.98%
controls:0.84%
—
0
5
240
2377
—
—
—
—
9
19
217
2249
Medical Oncology
90 [38004507]
90 [38004507]
—
5.5e-01
—
—
—
1.1e+00
1.6e+00
—
—
cases:2.08%
controls:1.22%
—
—
—
—
—
—
cases:3.36%
controls:1.18%
cases:8.41%
controls:1.90%
—
5
29
235
2353
—
—
—
8
28
230
2336
19
43
207
2225
Day surgery
ZXD20 [2001311388]
ZXD20 [2001311388]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.42%
controls:0.97%
—
—
—
—
—
—
10
22
216
2246
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
7.9e-01
1.5e+00
—
1.0e+50
—
1.4e+00
1.5e+00
cases:4.18%
controls:1.94%
cases:2.50%
controls:0.55%
—
—
cases:2.08%
controls:0.00%
—
—
cases:2.10%
controls:0.55%
cases:6.64%
controls:1.50%
10
46
229
2326
6
13
234
2369
—
5
0
235
2382
—
5
13
233
2351
15
34
211
2234
Intravenous general anesthesia
WX404 [2001310807]
WX404 [2001310807]
-2.8e-02
—
—
—
—
1.4e+00
1.5e+00
cases:2.09%
controls:2.15%
—
—
—
—
—
—
—
—
cases:2.10%
controls:0.51%
cases:6.19%
controls:1.50%
5
51
234
2321
—
—
—
—
5
12
233
2352
14
34
212
2234
More than three and less than five hours
ZXE20 [2001311408]
ZXE20 [2001311408]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.87%
controls:1.19%
—
—
—
—
—
—
11
27
215
2241
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
2.0e-01
2.1e-01
—
—
—
8.5e-01
5.9e-01
cases:9.62%
controls:8.01%
cases:4.17%
controls:3.40%
—
—
—
—
—
—
cases:8.82%
controls:3.98%
cases:22.12%
controls:13.62%
23
190
216
2182
10
81
230
2301
—
—
—
21
94
217
2270
50
309
176
1959
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
-7.4e-02
7.8e-01
—
—
—
4.1e-01
1.4e+00
cases:2.51%
controls:2.70%
cases:3.33%
controls:1.55%
—
—
—
—
—
—
cases:2.52%
controls:1.69%
cases:14.16%
controls:3.84%
6
64
233
2308
8
37
232
2345
—
—
—
6
40
232
2324
32
87
194
2181
gabapentin; oral
N02BF01 [955005]
N02BF01 [955005]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.64%
controls:1.85%
—
—
—
—
—
—
15
42
211
2226
Oncology Clinic/Center
261QX0200X [38004268]
261QX0200X [38004268]
1.2e-01
1.7e+00
—
—
—
1.5e+00
1.3e+00
cases:2.51%
controls:2.23%
cases:2.92%
controls:0.55%
—
—
—
—
—
—
cases:2.52%
controls:0.55%
cases:7.08%
controls:1.98%
6
53
233
2319
7
13
233
2369
—
—
—
6
13
232
2351
16
45
210
2223
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
8.7e-01
—
—
—
—
—
1.3e+00
cases:2.09%
controls:0.89%
—
—
—
—
—
—
—
—
—
—
cases:5.31%
controls:1.54%
5
21
234
2351
—
—
—
—
—
12
35
214
2233
Audiology
64 [38004489]
64 [38004489]
—
1.4e+00
—
—
—
1.5e+00
1.2e+00
—
—
cases:2.08%
controls:0.55%
—
—
—
—
—
—
cases:2.52%
controls:0.55%
cases:5.31%
controls:1.59%
—
5
13
235
2369
—
—
—
6
13
232
2351
12
36
214
2232
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.64%
controls:2.03%
—
—
—
—
—
—
15
46
211
2222
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
2.7e-01
—
—
—
—
1.1e+00
1.2e+00
cases:2.09%
controls:1.60%
—
—
—
—
—
—
—
—
cases:3.36%
controls:1.10%
cases:7.52%
controls:2.38%
5
38
234
2334
—
—
—
—
8
26
230
2338
17
54
209
2214
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
4.5e-01
—
-1.0e+50
—
—
—
1.2e+00
cases:2.09%
controls:1.35%
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
cases:6.64%
controls:2.12%
5
32
234
2340
—
0
5
240
2377
—
—
—
15
48
211
2220
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
6.3e-01
—
—
—
—
—
1.2e+00
cases:2.51%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
cases:6.64%
controls:2.12%
6
32
233
2340
—
—
—
—
—
15
48
211
2220
fusidic acid
D09AA02 [21602265]
D09AA02 [21602265]
3.9e-01
—
—
—
—
1.6e+00
1.2e+00
cases:3.77%
controls:2.57%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.63%
cases:6.19%
controls:1.98%
9
61
230
2311
—
—
—
—
7
15
231
2349
14
45
212
2223
fusidic acid; ointment
D06AX01 [21602062]
D06AX01 [21602062]
3.9e-01
—
—
—
—
1.6e+00
1.2e+00
cases:3.77%
controls:2.57%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.63%
cases:6.19%
controls:1.98%
9
61
230
2311
—
—
—
—
7
15
231
2349
14
45
212
2223
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
6.6e-01
—
—
—
—
—
1.2e+00
cases:2.51%
controls:1.31%
—
—
—
—
—
—
—
—
—
—
cases:7.08%
controls:2.34%
6
31
233
2341
—
—
—
—
—
16
53
210
2215
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
2.2e-01
—
—
—
—
8.0e-01
1.1e+00
cases:2.51%
controls:2.02%
—
—
—
—
—
—
—
—
cases:3.78%
controls:1.73%
cases:9.73%
controls:3.44%
6
48
233
2324
—
—
—
—
9
41
229
2323
22
78
204
2190
Right side
ZXA00 [2001311346]
ZXA00 [2001311346]
6.2e-01
7.0e-01
—
—
—
1.1e+00
1.1e+00
cases:2.93%
controls:1.60%
cases:2.08%
controls:1.05%
—
—
—
—
—
—
cases:2.52%
controls:0.89%
cases:7.08%
controls:2.56%
7
38
232
2334
5
25
235
2357
—
—
—
6
21
232
2343
16
58
210
2210
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
2.6e-01
—
—
—
—
1.3e+00
1.0e+00
cases:6.28%
controls:4.93%
—
—
—
—
—
—
—
—
cases:4.20%
controls:1.14%
cases:11.06%
controls:4.23%
15
117
224
2255
—
—
—
—
10
27
228
2337
25
96
201
2172
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
4.3e-01
—
—
—
-1.0e+50
—
1.0e+00
cases:2.51%
controls:1.64%
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
cases:6.64%
controls:2.47%
6
39
233
2333
—
—
—
0
5
240
2375
—
15
56
211
2212
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
2.2e-01
—
—
—
—
9.0e-01
1.0e+00
cases:3.35%
controls:2.70%
—
—
—
—
—
—
—
—
cases:3.78%
controls:1.57%
cases:8.85%
controls:3.44%
8
64
231
2308
—
—
—
—
9
37
229
2327
20
78
206
2190
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
3.1e-01
1.0e+00
—
—
—
1.3e+00
1.0e+00
cases:2.51%
controls:1.85%
cases:2.08%
controls:0.76%
—
—
—
—
—
—
cases:3.36%
controls:0.97%
cases:7.08%
controls:2.73%
6
44
233
2328
5
18
235
2364
—
—
—
8
23
230
2341
16
62
210
2206
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
5.1e-01
—
—
—
—
—
9.8e-01
cases:2.51%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
cases:7.52%
controls:2.95%
6
36
233
2336
—
—
—
—
—
17
67
209
2201
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-1.0e+00
-1.5e+00
—
—
—
—
3.5e+00
cases:9.21%
controls:21.75%
cases:2.08%
controls:8.65%
—
—
—
—
—
—
—
—
cases:7.96%
controls:0.26%
22
516
217
1856
5
206
235
2176
—
—
—
—
18
6
208
2262
Psychiatry
26 [38004469]
26 [38004469]
-1.3e-01
4.0e-01
—
—
8.4e-01
7.7e-01
9.5e-01
cases:3.35%
controls:3.79%
cases:3.33%
controls:2.27%
—
—
—
—
cases:2.50%
controls:1.09%
cases:5.04%
controls:2.41%
cases:12.39%
controls:5.20%
8
90
231
2282
8
54
232
2328
—
—
6
26
234
2354
12
57
226
2307
28
118
198
2150
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
1.8e-01
3.4e-02
—
—
—
7.8e-01
9.3e-01
cases:3.35%
controls:2.82%
cases:2.08%
controls:2.02%
—
—
—
—
—
—
cases:3.78%
controls:1.78%
cases:9.73%
controls:4.10%
8
67
231
2305
5
48
235
2334
—
—
—
9
42
229
2322
22
93
204
2175
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
—
—
—
—
—
3.6e-01
9.1e-01
—
—
—
—
—
—
—
—
—
—
cases:2.10%
controls:1.48%
cases:8.85%
controls:3.75%
—
—
—
—
—
5
35
233
2329
20
85
206
2183
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
N02AX02 [21604298]
5.7e-01
9.4e-01
—
—
—
7.7e-01
8.4e-01
cases:7.53%
controls:4.38%
cases:4.58%
controls:1.85%
—
—
—
—
—
—
cases:4.20%
controls:1.99%
cases:10.18%
controls:4.67%
18
104
221
2268
11
44
229
2338
—
—
—
10
47
228
2317
23
106
203
2162
Emergency Room Visit
ER [9203]
ER [9203]
1.8e-02
2.6e-01
—
1.0e+50
7.0e-01
-3.2e-03
5.1e-01
cases:26.78%
controls:26.43%
cases:12.92%
controls:10.24%
—
—
cases:2.08%
controls:0.00%
cases:2.50%
controls:1.26%
cases:10.92%
controls:10.96%
cases:42.04%
controls:30.29%
64
627
175
1745
31
244
209
2138
—
5
0
235
2382
6
30
234
2350
26
259
212
2105
95
687
131
1581
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
1.3e+00
—
—
—
—
—
9.8e-01
cases:2.09%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:3.10%
controls:1.19%
5
14
234
2358
—
—
—
—
—
7
27
219
2241
Insulin-dependent diabetes diabetic hypoglycemic coma
E10.00 [2000501424]
E10.00 [2000501424]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
0
13
239
2359
—
—
—
—
—
0
9
226
2259
Other complicated additional procedure necessary for restorative treatment
SFC92 [2001310370]
SFC92 [2001310370]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
239
2358
—
—
—
—
—
—
General and Unspecified, Clarification/discussion RFE/demand
A48 [2002000182]
A48 [2002000182]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
12
226
2256
Other primary arthrosis of first carpometacarpal joint
M18.1 [45538684]
M18.1 [45538684]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Plastic operation of joint cartilage of knee
NGF35 [2001308135]
NGF35 [2001308135]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
239
2366
—
—
—
—
—
—
chondroitin sulfate
M01AX25 [21604013]
M01AX25 [21604013]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
239
2363
—
—
—
—
—
—
Extensive global examination
SPAT1360 [2001700461]
SPAT1360 [2001700461]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
239
2363
—
—
—
—
—
—
ciclesonide; inhalant
R03BA08 [21603291]
R03BA08 [21603291]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
239
2363
—
—
—
—
—
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
14732-2 [3021960]
-1.0e+50
—
—
—
—
—
1.6e-01
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:1.90%
0
16
239
2356
—
—
—
—
—
5
43
221
2225
Adenotonsillectomy
EMB20 [2001302267]
EMB20 [2001302267]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
Insertion of central venous catheter through subclavian or brachiocephalic vein
TPH20 [2001309601]
TPH20 [2001309601]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
0
7
239
2365
—
—
—
—
—
0
5
226
2263
Diabetic maculopathy and Type 1 diabetes mellitus, With ophthalmic complications
H36.01*E10.3 [2000503946]
H36.01*E10.3 [2000503946]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.57%
0
8
239
2364
0
5
240
2377
—
—
—
0
5
238
2359
0
13
226
2255
Laceration/cut
S18 [2002000983]
S18 [2002000983]
2.7e-02
1.1e+00
—
—
2.0e+00
5.8e-01
6.8e-01
cases:2.51%
controls:2.45%
cases:2.50%
controls:0.84%
—
—
—
—
cases:2.08%
controls:0.29%
cases:2.10%
controls:1.18%
cases:8.85%
controls:4.67%
6
58
233
2314
6
20
234
2362
—
—
5
7
235
2373
5
28
233
2336
20
106
206
2162
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
-7.9e-02
-2.4e-01
—
—
—
-6.9e-03
1.9e-01
cases:2.93%
controls:3.16%
cases:2.08%
controls:2.64%
—
—
—
—
—
—
cases:2.52%
controls:2.54%
cases:6.19%
controls:5.16%
7
75
232
2297
5
63
235
2319
—
—
—
6
60
232
2304
14
117
212
2151
Noninfective gastroenteritis and colitis, unspecified
K52.9 [45572215]
K52.9 [45572215]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
6
226
2262
hydrocortisone buteprate
D07AB11 [21602115]
D07AB11 [21602115]
6.1e-02
4.2e-01
-1.0e+50
—
—
—
9.6e-02
cases:6.69%
controls:6.32%
cases:2.92%
controls:1.93%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:7.52%
controls:6.88%
16
150
223
2222
7
46
233
2336
0
7
240
2375
—
—
—
17
156
209
2112
fexofenadine; oral
R06AX26 [21603525]
R06AX26 [21603525]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
239
2357
—
—
—
—
—
—
Neck ultrasound examination
EP1AE [2001302284]
EP1AE [2001302284]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
239
2366
—
—
—
—
—
—
dexamethasone
D10AA03 [21602286]
D10AA03 [21602286]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
0
5
240
2377
—
—
—
—
—
Other blockage of nerve
WX290 [2001310792]
WX290 [2001310792]
-3.3e-01
—
-1.0e+50
—
—
—
-2.0e-01
cases:3.35%
controls:4.60%
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
cases:7.08%
controls:8.51%
8
109
231
2263
—
0
5
240
2377
—
—
—
16
193
210
2075
tizanidine; oral
M03BX02 [21604116]
M03BX02 [21604116]
-5.5e-02
2.1e-01
—
—
-1.0e+50
4.6e-03
1.4e-01
cases:10.88%
controls:11.42%
cases:4.58%
controls:3.74%
—
—
—
—
cases:0.00%
controls:0.38%
cases:3.78%
controls:3.76%
cases:13.72%
controls:12.13%
26
271
213
2101
11
89
229
2293
—
—
0
9
240
2371
9
89
229
2275
31
275
195
1993
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
10886-0 [3005013]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
0
16
238
2348
—
General medical examination
Z00.0 [45585791]
Z00.0 [45585791]
—
—
—
—
—
-1.0e+50
6.7e-02
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:2.21%
controls:2.07%
—
—
—
—
—
0
8
238
2356
5
47
221
2221
diltiazem; oral
C08DB01 [21601771]
C08DB01 [21601771]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
239
2366
—
—
—
—
—
—
Proteinase 3 Ab [Units/volume] in Serum
6968-2 [3009445]
6968-2 [3009445]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
Orthodontic treatment/control appointment
SJX20 [2001310454]
SJX20 [2001310454]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
6
239
2366
—
—
—
—
—
0
6
226
2262
Physical abuse
T74.1 [45594864]
T74.1 [45594864]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
6
226
2262
Chondromalacia patellae
M22.4 [45538712]
M22.4 [45538712]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
239
2362
—
—
—
—
—
—
Social phobias
F40.1 [45595907]
F40.1 [45595907]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
0
8
226
2260
lansoprazole; oral
A02BC03 [21600098]
A02BC03 [21600098]
-2.4e-01
—
-1.0e+50
—
-1.0e+50
—
2.5e-01
cases:2.51%
controls:3.16%
—
—
cases:0.00%
controls:0.38%
—
—
cases:0.00%
controls:0.21%
—
—
cases:5.31%
controls:4.19%
6
75
233
2297
—
0
9
240
2373
—
0
5
240
2375
—
12
95
214
2173
Glaucoma suspect
H40.0 [45567051]
H40.0 [45567051]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
0
5
240
2377
—
—
—
—
—
Neck symptom/complaint
L01 [2002000626]
L01 [2002000626]
—
—
—
—
—
-1.0e+50
9.3e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
cases:2.21%
controls:0.88%
—
—
—
—
—
0
11
238
2353
5
20
221
2248
ipratropium bromide; inhalant
R03BB01 [21603293]
R03BB01 [21603293]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
0
5
240
2377
—
—
—
—
0
10
226
2258
Dietary counselling and surveillance
Z71.3 [45552101]
Z71.3 [45552101]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
WYA05 [2001310871]
-1.9e-01
-2.6e-01
—
—
—
-1.2e-01
-3.6e-01
cases:4.60%
controls:5.52%
cases:2.08%
controls:2.69%
—
—
—
—
—
—
cases:2.10%
controls:2.37%
cases:5.75%
controls:8.02%
11
131
228
2241
5
64
235
2318
—
—
—
5
56
233
2308
13
182
213
2086
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
5.9e-02
-2.4e-01
—
—
—
-1.4e-01
3.1e-01
cases:3.35%
controls:3.16%
cases:2.08%
controls:2.64%
—
—
—
—
—
—
cases:2.52%
controls:2.88%
cases:7.08%
controls:5.29%
8
75
231
2297
5
63
235
2319
—
—
—
6
68
232
2296
16
120
210
2148
Root filling of tooth with onetwo root canals
SGB20 [2001310389]
SGB20 [2001310389]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
0
5
238
2359
—
Gonarthrosis, unspecified
M17.9 [45606128]
M17.9 [45606128]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
0
5
239
2367
—
—
—
—
—
0
20
226
2248
fluticasone furoate; nasal
R01AD12 [21605053]
R01AD12 [21605053]
7.5e-02
-2.6e-01
—
—
—
-1.4e-01
-3.2e-01
cases:6.69%
controls:6.24%
cases:2.08%
controls:2.69%
—
—
—
—
—
—
cases:2.10%
controls:2.41%
cases:5.31%
controls:7.14%
16
148
223
2224
5
64
235
2318
—
—
—
5
57
233
2307
12
162
214
2106
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
D01AE20 [21601959]
—
—
—
—
—
—
2.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.65%
controls:2.12%
—
—
—
—
—
—
6
48
220
2220
betaxolol; oral
C07AB05 [21601687]
C07AB05 [21601687]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.38%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
0
9
239
2363
0
5
240
2377
—
—
—
—
—
HLA-B27 [Presence]
4821-5 [3008898]
4821-5 [3008898]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
0
10
226
2258
Procedure duration 60 to 89 minutes
ZXE11 [2001311402]
ZXE11 [2001311402]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
0
6
239
2366
0
14
240
2368
—
—
—
—
—
Medical abortion, complete or unspecified, without complication
O04.9 [45543909]
O04.9 [45543909]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.67%
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
0
16
239
2356
0
6
240
2376
—
—
—
—
—
flucloxacillin; oral, parenteral
J01CF05 [21602857]
J01CF05 [21602857]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
Persistent somatoform pain disorder
F45.4 [45605498]
F45.4 [45605498]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
7
226
2261
Irregular menstruation, unspecified
N92.6 [45539075]
N92.6 [45539075]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
239
2359
—
—
—
—
—
—
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
-1.2e-01
-4.8e-02
—
—
—
2.2e-01
5.8e-01
cases:4.18%
controls:4.68%
cases:2.08%
controls:2.18%
—
—
—
—
—
—
cases:2.94%
controls:2.37%
cases:13.72%
controls:8.16%
10
111
229
2261
5
52
235
2330
—
—
—
7
56
231
2308
31
185
195
2083
Exposure to other specified factors
X58 [45756411]
X58 [45756411]
—
-1.0e+50
—
—
—
—
4.9e-01
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
cases:2.21%
controls:1.37%
—
0
6
240
2376
—
—
—
—
5
31
221
2237
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
1.2e-01
4.3e-01
—
—
—
2.0e-01
2.4e-01
cases:2.51%
controls:2.23%
cases:2.50%
controls:1.64%
—
—
—
—
—
—
cases:2.52%
controls:2.07%
cases:7.96%
controls:6.35%
6
53
233
2319
6
39
234
2343
—
—
—
6
49
232
2315
18
144
208
2124
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
6.3e-02
3.6e-01
—
—
—
1.4e-01
1.8e-01
cases:2.51%
controls:2.36%
cases:2.50%
controls:1.76%
—
—
—
—
—
—
cases:2.52%
controls:2.20%
cases:7.96%
controls:6.75%
6
56
233
2316
6
42
234
2340
—
—
—
6
52
232
2312
18
153
208
2115
Other therapy enhancing rehabilitation
R4160 [2001310240]
R4160 [2001310240]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
7
226
2261
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
2500B [2000402295]
2500B [2000402295]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.26%
—
—
—
—
—
—
—
—
—
—
—
—
0
30
239
2342
—
—
—
—
—
—
Trisomy 18 risk [Likelihood] in Fetus
43994-3 [3047352]
43994-3 [3047352]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
Treatment-related counselling outside office
SPAT1249 [2001700350]
SPAT1249 [2001700350]
—
—
—
—
—
1.2e-01
-4.1e-01
—
—
—
—
—
—
—
—
—
—
cases:2.10%
controls:1.86%
cases:4.42%
controls:6.53%
—
—
—
—
—
5
44
233
2320
10
148
216
2120
cetirizine; oral
R06AE07 [21603497]
R06AE07 [21603497]
-3.4e-01
-3.0e-01
—
—
-1.0e+50
1.1e-01
3.4e-01
cases:6.69%
controls:9.15%
cases:3.33%
controls:4.45%
—
—
—
—
cases:0.00%
controls:0.46%
cases:4.62%
controls:4.15%
cases:10.62%
controls:7.80%
16
217
223
2155
8
106
232
2276
—
—
0
11
240
2369
11
98
227
2266
24
177
202
2091
Infective dermatitis
L30.3 [45577034]
L30.3 [45577034]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Repair of umbilical hernia
JAF10 [2001304441]
JAF10 [2001304441]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Mild cervical dysplasia
N87.0 [45567868]
N87.0 [45567868]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
0
5
239
2367
—
—
—
—
—
0
9
226
2259
Pregnancy
W78 [2002001269]
W78 [2002001269]
—
—
-1.0e+50
—
-1.0e+50
—
2.1e-01
—
—
—
—
cases:0.00%
controls:0.21%
—
—
cases:0.00%
controls:0.25%
—
—
cases:2.21%
controls:1.81%
—
—
0
5
240
2377
—
0
6
240
2374
—
5
41
221
2227
dapagliflozin; oral
A10BK01 [1123890]
A10BK01 [1123890]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
13
226
2255
Ulcerative colitis and Crohn's disease
208 [2001600206]
208 [2001600206]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
6
226
2262
acetylsalicylic acid; oral
B01AC06 [21600991]
B01AC06 [21600991]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
12
238
2352
—
Shortness of breath/dyspnoea
R02 [2002000883]
R02 [2002000883]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
0
8
239
2364
—
—
—
—
0
7
238
2357
—
Rhinovirus RNA [Presence] in Specimen by NAA with probe detection
7993-9 [3025023]
7993-9 [3025023]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
pH of Capillary blood
2745-8 [3009343]
2745-8 [3009343]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
0
7
238
2357
—
clarithromycin; oral, parenteral
J01FA09 [21602977]
J01FA09 [21602977]
1.4e-01
—
—
—
—
—
-4.2e-01
cases:5.44%
controls:4.76%
—
—
—
—
—
—
—
—
—
—
cases:3.10%
controls:4.63%
13
113
226
2259
—
—
—
—
—
7
105
219
2163
tetracycline; oral, parenteral
J01AA07 [21602805]
J01AA07 [21602805]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
14
238
2350
—
False labour at or after 37 completed weeks of gestation
O47.1 [45558317]
O47.1 [45558317]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Teaching of medicine inhalation technique
SPAT1257 [2001700358]
SPAT1257 [2001700358]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
6
226
2262
nimesulide; oral
M01AX17 [21604007]
M01AX17 [21604007]
2.7e-02
—
—
—
—
—
—
cases:2.51%
controls:2.45%
—
—
—
—
—
—
—
—
—
—
—
—
6
58
233
2314
—
—
—
—
—
—
Shoulder X-ray examination without contrast
NB1AA [2001307225]
NB1AA [2001307225]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
0
9
239
2363
—
—
—
—
—
0
10
226
2258
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
2075-0 [3014576]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.10%
controls:0.88%
—
—
—
—
—
—
7
20
219
2248
Recurrent depressive disorder, unspecified
F33.9 [45581458]
F33.9 [45581458]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
ofloxacin
S01AE01 [43534856]
S01AE01 [43534856]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
239
2358
—
—
—
—
—
—
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
24351-9 [3004588]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
0
5
240
2377
—
—
—
—
—
Type 1 diabetes mellitus, With ophthalmic complications
E10.3 [45552380]
E10.3 [45552380]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:0.59%
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.68%
—
—
0
23
239
2349
0
14
240
2368
—
—
0
5
240
2375
0
16
238
2348
—
Sciatica
M54.3 [45586994]
M54.3 [45586994]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.57%
0
6
239
2366
—
—
—
—
0
5
238
2359
0
13
226
2255
Thyrotoxicosis, unspecified
E05.9 [45586131]
E05.9 [45586131]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
0
7
239
2365
—
—
—
—
—
0
5
226
2263
Insect bite/sting
S12 [2002000977]
S12 [2002000977]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
0
6
240
2376
—
—
—
—
—
Emotionally unstable personality disorder, borderline condition
F60.31 [2000502023]
F60.31 [2000502023]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Eye discharge
F03 [2002000401]
F03 [2002000401]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
239
2366
—
—
—
—
—
—
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
72171-2 [43054914]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
0
14
240
2368
—
—
—
0
8
238
2356
—
Red eye
F02 [2002000400]
F02 [2002000400]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
Oral Surgery
19 [38004464]
19 [38004464]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
Recurrent depression, mild episode without somatic syndrome
F33.00 [2000501982]
F33.00 [2000501982]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Antenatal classes
SPAT1195 [2001700296]
SPAT1195 [2001700296]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
6
226
2262
Palpitations/awareness of heart
K04 [2002000547]
K04 [2002000547]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
pimecrolimus
D11AH02 [21602339]
D11AH02 [21602339]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
Immunofixation for Serum or Plasma
25700-6 [3037756]
25700-6 [3037756]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
Second degree perineal laceration during delivery
O70.1 [45572890]
O70.1 [45572890]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
7
226
2261
Medical observation and evaluation for suspected diseases and conditions, ruled out
Z03 [45552058]
Z03 [45552058]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
0
9
240
2373
—
—
—
—
—
nizatidine; oral, parenteral
A02BA04 [21600085]
A02BA04 [21600085]
1.4e+00
—
—
—
—
—
—
cases:2.09%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
5
12
234
2360
—
—
—
—
—
—
Toothache NOS
K08.80 [2000502799]
K08.80 [2000502799]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
0
5
240
2377
—
—
—
—
0
16
226
2252
COVID-19, virus not identified
U07.2 [45756094]
U07.2 [45756094]
—
—
—
—
—
-1.0e+50
3.7e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:2.21%
controls:1.54%
—
—
—
—
—
0
6
238
2358
5
35
221
2233
rizatriptan; oral
N02CC04 [21604379]
N02CC04 [21604379]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
7
240
2375
—
—
—
—
—
Pregnancy symptom/complaint other
W29 [2002001222]
W29 [2002001222]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
2021-4 [3021447]
—
-1.0e+50
—
—
—
—
1.6e+00
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:3.10%
controls:0.66%
—
0
11
240
2371
—
—
—
—
7
15
219
2253
Moderate depressive episode
F32.1 [45552478]
F32.1 [45552478]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]
J07AL02 [21601313]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
620-5 [3007853]
—
—
—
—
—
—
4.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:1.41%
—
—
—
—
—
—
5
32
221
2236
Functional dyspepsia
K30 [45591584]
K30 [45591584]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
12
226
2256
verapamil; oral, parenteral
C08DA01 [21601767]
C08DA01 [21601767]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
7
240
2375
—
—
—
—
—
Midwife
Z3232 [2001311563]
Z3232 [2001311563]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
239
2357
—
—
—
—
—
—
Severe depressive episode with psychotic symptoms
F32.3 [45600739]
F32.3 [45600739]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
phenylephrine, combinations
R01BA53 [21603214]
R01BA53 [21603214]
-2.5e-01
-1.0e+50
—
—
—
—
—
cases:3.77%
controls:4.81%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
9
114
230
2258
0
12
240
2370
—
—
—
—
—
Urology
34 [38004474]
34 [38004474]
2.7e-01
1.0e+00
—
—
—
—
6.9e-01
cases:2.09%
controls:1.60%
cases:2.50%
controls:0.92%
—
—
—
—
—
—
—
—
cases:4.87%
controls:2.51%
5
38
234
2334
6
22
234
2360
—
—
—
—
11
57
215
2211
hydrocortisone
S02BA01 [21605166]
S02BA01 [21605166]
-2.0e-01
4.6e-01
-1.0e+50
—
—
—
7.0e-02
cases:4.60%
controls:5.56%
cases:2.50%
controls:1.60%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:6.64%
controls:6.22%
11
132
228
2240
6
38
234
2344
0
7
240
2375
—
—
—
15
141
211
2127
phenoxymethylpenicillin; oral
J01CE02 [21602842]
J01CE02 [21602842]
-2.1e-01
3.9e-02
—
—
—
-3.7e-01
3.2e-01
cases:11.30%
controls:13.62%
cases:3.75%
controls:3.61%
—
—
—
—
—
—
cases:2.52%
controls:3.60%
cases:18.14%
controls:13.84%
27
323
212
2049
9
86
231
2296
—
—
—
6
85
232
2279
41
314
185
1954
Supervision of normal pregnancy, unspecified
Z34.9 [45566420]
Z34.9 [45566420]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
—
0
8
240
2374
—
—
—
—
—
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]
2874-6 [3023465]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
-1.0e+50
—
—
—
—
—
1.1e+00
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
cases:3.10%
controls:1.06%
0
6
239
2366
—
—
—
—
—
7
24
219
2244
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
N02CC01 [21604376]
—
—
—
—
—
—
1.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.54%
controls:2.95%
—
—
—
—
—
—
8
67
218
2201
Spontaneous abortion, Complete or unspecified, without complication
O03.9 [45563040]
O03.9 [45563040]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
SPAT1306 [2001700407]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
0
9
238
2355
—
calcipotriol; ointment
D05AX02 [21602039]
D05AX02 [21602039]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
239
2363
—
—
—
—
—
—
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
4548-4 [3004410]
5.4e-02
-1.9e-01
-1.0e+50
—
—
7.1e-02
8.7e-02
cases:6.69%
controls:6.37%
cases:3.75%
controls:4.49%
cases:0.00%
controls:0.80%
—
—
—
—
cases:5.88%
controls:5.50%
cases:14.16%
controls:13.14%
16
151
223
2221
9
107
231
2275
0
19
240
2363
—
—
14
130
224
2234
32
298
194
1970
doxylamine; oral
R06AA09 [21603453]
R06AA09 [21603453]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
Senile macular degeneration (atrophic)(exudative)
H35.31 [2000502315]
H35.31 [2000502315]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
ECG with 12 standard connections
XF400 [2001303368]
XF400 [2001303368]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
0
8
238
2356
—
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
Hip X-ray examination
NF1AA [2001307894]
NF1AA [2001307894]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
239
2366
—
—
—
—
—
—
Problems related to unwanted pregnancy
Z64.0 [45581053]
Z64.0 [45581053]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
N02AB03 [21604272]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.22%
—
—
—
—
—
—
5
5
221
2263
Other angina pectoris stenosed coronary artery
I20.81 [2000502397]
I20.81 [2000502397]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
0
11
239
2361
—
—
—
—
—
0
8
226
2260
Endometriosis, unspecified
N80.9 [45543892]
N80.9 [45543892]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
2.2e-01
6.0e-01
—
—
—
—
2.0e-01
cases:2.51%
controls:2.02%
cases:2.50%
controls:1.39%
—
—
—
—
—
—
—
—
cases:6.64%
controls:5.51%
6
48
233
2324
6
33
234
2349
—
—
—
—
15
125
211
2143
IgG subclass 1 [Mass/volume] in Serum
2466-1 [3027135]
2466-1 [3027135]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
239
2366
—
—
—
—
—
—
Ultrasound examination of early pregnancy (before 12. postmenstrual week)
MA1AE [2001306827]
MA1AE [2001306827]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.05%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
0
25
239
2347
0
5
240
2377
—
—
—
—
—
Antenatal screening for malformation
717800004 [36713462]
717800004 [36713462]
-1.1e-01
—
—
—
-1.0e+50
—
6.4e-02
cases:2.51%
controls:2.78%
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
cases:3.10%
controls:2.91%
6
66
233
2306
—
—
—
0
5
240
2375
—
7
66
219
2202
Low back symptom/complaint
L03 [2002000628]
L03 [2002000628]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
0
15
240
2367
—
—
—
0
12
238
2352
—
Teeth/gum symptom/complaint
D19 [2002000318]
D19 [2002000318]
—
—
—
—
—
—
-4.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:3.44%
—
—
—
—
—
—
5
78
221
2190
Assessment of need for psychiatric treatment
IAA01 [2001304011]
IAA01 [2001304011]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
6
226
2262
Blepharitis
H01.0 [45533180]
H01.0 [45533180]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
239
2366
—
—
—
—
—
—
Localized swelling, mass and lump, unspecified
R22.9 [45577788]
R22.9 [45577788]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
10
239
2362
—
—
—
—
—
0
11
226
2257
mesalazine; oral, rectal
A07EC02 [21600664]
A07EC02 [21600664]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
0
16
238
2348
—
Naevus, non-neoplastic
I78.1 [45533504]
I78.1 [45533504]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
choriogonadotropin alfa; parenteral
G03GA08 [21602606]
G03GA08 [21602606]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
terbinafine; oral
D01BA02 [21601967]
D01BA02 [21601967]
3.8e-01
—
—
—
—
—
8.0e-02
cases:2.93%
controls:2.02%
—
—
—
—
—
—
—
—
—
—
cases:3.10%
controls:2.87%
7
48
232
2324
—
—
—
—
—
7
65
219
2203
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
0
7
238
2357
—
fluocortolone
C05AA08 [21601612]
C05AA08 [21601612]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.88%
—
—
—
—
—
0
6
238
2358
0
20
226
2248
Mild depressive episode without somatic syndrome
F32.00 [2000501978]
F32.00 [2000501978]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
0
5
240
2377
—
—
—
—
—
Custom moulded cast, unspecified region
TNX33 [2001308564]
TNX33 [2001308564]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
14
226
2254
Guidance for breast-feeding and breast care
SPAT1200 [2001700301]
SPAT1200 [2001700301]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
0
8
226
2260
Other minor procedure in surgery of ear, nose and larynx
TDW99 [2001301879]
TDW99 [2001301879]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
furosemide and potassium-sparing agents
C03EB01 [21601554]
C03EB01 [21601554]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
0
5
238
2359
—
Methadone [Presence] in Urine by Screen method
19550-3 [3028707]
19550-3 [3028707]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
Cervicocranial syndrome
M53.0 [45562750]
M53.0 [45562750]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
10
239
2362
—
—
—
—
—
0
12
226
2256
Crushed, pushed or stepped on by crowd or human stampede
W52 [45756303]
W52 [45756303]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
239
2366
—
—
—
—
—
—
citalopram; oral, parenteral
N06AB04 [21604712]
N06AB04 [21604712]
—
—
-1.0e+50
—
-1.0e+50
—
4.9e-02
—
—
—
—
cases:0.00%
controls:0.34%
—
—
cases:0.00%
controls:0.42%
—
—
cases:3.10%
controls:2.95%
—
—
0
8
240
2374
—
0
10
240
2370
—
7
67
219
2201
Sampling
SPAT1263 [2001700364]
SPAT1263 [2001700364]
-1.7e-01
—
—
—
—
—
1.2e-02
cases:2.51%
controls:2.95%
—
—
—
—
—
—
—
—
—
—
cases:5.75%
controls:5.69%
6
70
233
2302
—
—
—
—
—
13
129
213
2139
Cerebral infarction due to embolism of cerebral arteries
I63.4 [45591475]
I63.4 [45591475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
triamterene; oral
C03DB02 [21601540]
C03DB02 [21601540]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Partial excision of meniscus of knee, arthroscopic
NGD05 [2001308109]
NGD05 [2001308109]
-1.0e+50
-1.0e+50
—
—
—
—
7.9e-01
cases:0.00%
controls:0.76%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
cases:2.21%
controls:1.01%
0
18
239
2354
0
5
240
2377
—
—
—
—
5
23
221
2245
Nonorganic insomnia
F51.0 [45552492]
F51.0 [45552492]
-1.0e+50
-1.0e+50
—
—
—
—
8.4e-01
cases:0.00%
controls:0.72%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.97%
0
17
239
2355
0
7
240
2375
—
—
—
—
5
22
221
2246
Alcohol-related acute intoxication uncomplicated
F10.00 [2000501668]
F10.00 [2000501668]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
temazepam; oral
N05CD07 [21604642]
N05CD07 [21604642]
5.6e-01
9.2e-01
—
—
—
—
8.8e-01
cases:2.93%
controls:1.69%
cases:2.08%
controls:0.84%
—
—
—
—
—
—
—
—
cases:3.54%
controls:1.50%
7
40
232
2332
5
20
235
2362
—
—
—
—
8
34
218
2234
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
9.8e-01
—
-1.0e+50
1.0e+50
—
1.2e+00
1.0e+00
cases:5.02%
controls:1.94%
—
—
cases:0.00%
controls:0.25%
cases:2.08%
controls:0.00%
—
—
cases:2.52%
controls:0.80%
cases:6.19%
controls:2.34%
12
46
227
2326
—
0
6
240
2376
5
0
235
2382
—
6
19
232
2345
14
53
212
2215
Other healthcare associate professional
Z3229 [2001311561]
Z3229 [2001311561]
—
—
—
—
—
—
8.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.93%
—
—
—
—
—
—
5
21
221
2247
methylprednisolone; oral, parenteral
H02AB04 [21602732]
H02AB04 [21602732]
4.1e-01
-1.0e+50
-1.0e+50
—
—
—
—
cases:2.09%
controls:1.39%
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
5
33
234
2339
0
13
240
2369
0
6
240
2376
—
—
—
—
Cardiac arrhythmia NOS
K80 [2002000607]
K80 [2002000607]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 [2002330113]
SMOKING-2-3-0 [2002330113]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.00%
—
—
—
—
—
—
5
0
221
2268
Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis
50796-2 [3029338]
50796-2 [3029338]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Other seropositive rheumatoid arthritis
M05.8 [45538634]
M05.8 [45538634]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
0
14
239
2358
0
9
240
2373
—
—
—
0
11
238
2353
—
dexrabeprazole
A02BC07 [45893509]
A02BC07 [45893509]
—
—
—
—
—
-1.0e+50
9.8e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:2.21%
controls:0.84%
—
—
—
—
—
0
5
238
2359
5
19
221
2249
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
0
6
240
2376
—
—
—
—
—
nystatin
D01AA01 [21601911]
D01AA01 [21601911]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
239
2363
—
—
—
—
—
—
Other general examinations
Z00.8 [45581001]
Z00.8 [45581001]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.66%
—
—
—
—
—
0
5
238
2359
0
15
226
2253
methylprednisolone, combinations
H02BX01 [21602747]
H02BX01 [21602747]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
6
226
2262
tafluprost
S01EE05 [21603714]
S01EE05 [21603714]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
0
6
240
2376
—
—
—
—
—
Albumin [Mass/volume] in Urine
1754-1 [3012516]
1754-1 [3012516]
7.0e-01
—
—
—
—
—
2.9e-01
cases:2.51%
controls:1.26%
—
—
—
—
—
—
—
—
—
—
cases:5.31%
controls:4.01%
6
30
233
2342
—
—
—
—
—
12
91
214
2177
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y83 [45552036]
Y83 [45552036]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.75%
—
—
—
—
—
—
5
17
221
2251
ramipril; oral
C09AA05 [21601789]
C09AA05 [21601789]
—
4.1e-01
—
—
—
2.4e-01
3.0e-02
—
—
cases:2.50%
controls:1.68%
—
—
—
—
—
—
cases:2.52%
controls:1.99%
cases:3.54%
controls:3.44%
—
6
40
234
2342
—
—
—
6
47
232
2317
8
78
218
2190
Outlet vacuum delivery
MAE00 [2001306882]
MAE00 [2001306882]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.53%
—
—
—
—
—
0
5
238
2359
0
12
226
2256
Gestational [pregnancy-induced] hypertension
O13 [45539091]
O13 [45539091]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
0
8
226
2260
Telehealth
OMOP5556618 [722455]
OMOP5556618 [722455]
-7.4e-02
2.8e-02
—
—
—
2.5e-01
7.5e-03
cases:8.79%
controls:9.40%
cases:5.00%
controls:4.87%
—
—
—
—
—
—
cases:5.88%
controls:4.65%
cases:15.93%
controls:15.83%
21
223
218
2149
12
116
228
2266
—
—
—
14
110
224
2254
36
359
190
1909
rabeprazole; oral
A02BC04 [21600099]
A02BC04 [21600099]
—
—
—
—
—
-1.0e+50
9.8e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:2.21%
controls:0.84%
—
—
—
—
—
0
5
238
2359
5
19
221
2249
antibiotics in combination with corticosteroids
D01AA20 [21601918]
D01AA20 [21601918]
—
—
—
—
—
-1.0e+50
5.9e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
cases:2.21%
controls:1.23%
—
—
—
—
—
0
9
238
2355
5
28
221
2240
Synovial cyst of popliteal space [Baker]
M71.2 [45596669]
M71.2 [45596669]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
0
5
226
2263
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
E11.7 [45561950]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.44%
0
5
239
2367
0
5
240
2377
—
—
—
0
5
238
2359
0
10
226
2258
Other Crohn disease
K50.8 [45533599]
K50.8 [45533599]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.26%
0
5
239
2367
0
5
240
2377
—
—
—
0
5
238
2359
0
6
226
2262
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
—
—
—
—
—
—
6.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.65%
controls:1.46%
—
—
—
—
—
—
6
33
220
2235
Shoulder lesion, unspecified
M75.9 [45557986]
M75.9 [45557986]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
6
226
2262
Acute spinal anesthesia for delivery
WX321 [2001310800]
WX321 [2001310800]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
239
2366
—
—
—
—
—
—
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
72872-5 [43534045]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
0
6
240
2376
—
—
—
0
5
238
2359
—
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
J01CR02 [21602863]
-2.3e-02
—
—
—
—
—
1.4e-01
cases:5.86%
controls:5.99%
—
—
—
—
—
—
—
—
—
—
cases:7.96%
controls:7.01%
14
142
225
2230
—
—
—
—
—
18
159
208
2109
Umbilical hernia without obstruction or gangrene
K42.9 [45591589]
K42.9 [45591589]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
Infectious Disease
44 [38004484]
44 [38004484]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.10%
controls:0.79%
—
—
—
—
—
—
7
18
219
2250
acetazolamide; oral, parenteral
S01EC01 [21603693]
S01EC01 [21603693]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
239
2365
—
—
—
—
—
—
Acute cystitis
N30.0 [45601724]
N30.0 [45601724]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.25%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
0
14
239
2358
0
6
240
2376
—
—
—
0
7
238
2357
—
naproxcinod
M01AE18 [40254094]
M01AE18 [40254094]
3.2e-01
7.7e-01
—
—
—
1.5e-01
5.0e-02
cases:13.81%
controls:10.41%
cases:7.08%
controls:3.40%
—
—
—
—
—
—
cases:4.20%
controls:3.64%
cases:9.73%
controls:9.30%
33
247
206
2125
17
81
223
2301
—
—
—
10
86
228
2278
22
211
204
2057
Inpatient Visit
IP [9201]
IP [9201]
1.2e-01
—
—
—
—
-1.0e+50
4.9e-01
cases:2.51%
controls:2.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:3.98%
controls:2.47%
6
53
233
2319
—
—
—
—
0
13
238
2351
9
56
217
2212
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
NK6QA [2001308500]
-1.0e+50
—
—
—
—
—
1.9e+00
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
cases:2.65%
controls:0.40%
0
5
239
2367
—
—
—
—
—
6
9
220
2259
Opening and preparing the root canals, extremely complicated
SGA04 [2001310382]
SGA04 [2001310382]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
0
5
238
2359
—
Other primary coxarthrosis
M16.1 [45591741]
M16.1 [45591741]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.79%
0
9
239
2363
—
—
—
—
0
5
238
2359
0
18
226
2250
Deviated nasal septum
J34.2 [45562448]
J34.2 [45562448]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
12
226
2256
Plugged feeling ear
H13 [2002000480]
H13 [2002000480]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
0
6
240
2376
—
—
—
0
10
238
2354
—
Type 2 diabetes mellitus, with neurological complications
E11.4 [45576442]
E11.4 [45576442]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
6
226
2262
calcium carbonate
A02AC01 [21600065]
A02AC01 [21600065]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
0
9
226
2259
Streptococcal tonsillitis
J03.0 [45601114]
J03.0 [45601114]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
0
6
239
2366
—
—
—
—
—
0
8
226
2260
Oral and dental health check by dental hygienist or dental assistant
SAB02 [2001310280]
SAB02 [2001310280]
—
—
—
—
—
—
7.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.65%
controls:1.23%
—
—
—
—
—
—
6
28
220
2240
Wedge excision of mammary gland
HAB40 [2001303928]
HAB40 [2001303928]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
Manual removal of placenta from delivered uterus
MBA30 [2001306935]
MBA30 [2001306935]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
6
226
2262
Insertion of (intrauterine) contraceptive device
Z30.1 [45537626]
Z30.1 [45537626]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
239
2359
—
—
—
—
—
—
electrolytes
B05BB01 [21601161]
B05BB01 [21601161]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
6
226
2262
naproxen; oral, rectal
M01AE02 [21603968]
M01AE02 [21603968]
3.2e-01
7.7e-01
—
—
—
1.5e-01
5.0e-02
cases:13.81%
controls:10.41%
cases:7.08%
controls:3.40%
—
—
—
—
—
—
cases:4.20%
controls:3.64%
cases:9.73%
controls:9.30%
33
247
206
2125
17
81
223
2301
—
—
—
10
86
228
2278
22
211
204
2057
Cervical spine MRI examination with high intensity magnet
NA1BG [2001306990]
NA1BG [2001306990]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
239
2363
—
—
—
—
—
—
Memory disturbance
P20 [2002000816]
P20 [2002000816]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
Pain localized to other parts of lower abdomen
R10.3 [45534426]
R10.3 [45534426]
—
—
—
—
—
—
6.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.98%
controls:2.20%
—
—
—
—
—
—
9
50
217
2218
ethinylestradiol; oral
G03CA01 [21602516]
G03CA01 [21602516]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
6
239
2366
—
—
—
—
—
0
6
226
2262
Extensive health check-up at 18 months of age
SPAT1382 [2001700482]
SPAT1382 [2001700482]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
0
7
238
2357
—
Public health laboratory ask at order entry panel
81959-9 [21494755]
81959-9 [21494755]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
0
5
238
2359
—
levonorgestrel
G03AC03 [21602499]
G03AC03 [21602499]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
0
11
240
2371
—
—
—
0
9
238
2355
—
telmisartan and diuretics
C09DA07 [21601839]
C09DA07 [21601839]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
0
14
239
2358
0
11
240
2371
0
5
240
2377
—
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: Unspecified
SMOKING-1-1-0 [2002330116]
SMOKING-1-1-0 [2002330116]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
0
20
240
2362
—
—
—
—
—
Percutaneous or transvaginal puncture and recovery of oocyte
LAA10 [2001306406]
LAA10 [2001306406]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
239
2367
—
—
—
—
—
—
ferrous glycine sulfate; oral
B03AA01 [21601080]
B03AA01 [21601080]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
0
8
226
2260
Presence of intraocular lens
Z96.1 [45585885]
Z96.1 [45585885]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
0
9
239
2363
—
—
—
—
0
8
238
2356
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
-1.3e-01
-2.2e-01
—
—
—
-2.6e-01
5.1e-01
cases:3.35%
controls:3.79%
cases:2.50%
controls:3.11%
—
—
—
—
—
—
cases:2.52%
controls:3.26%
cases:10.18%
controls:6.35%
8
90
231
2282
6
74
234
2308
—
—
—
6
77
232
2287
23
144
203
2124
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
18
20
9.60
9.19
3.6
2.8
2.16
2.86
nmol/l
0.36
18
20
48
194
2.82
8.62
7.6
13.4
-0.40
0.89
mmol/l
1.45
36
160
132
877
2.06
7.31
7.8
7.4
1.20
1.22
mmol/l
2.30
125
816
137
965
1.92
6.01
8.7
8.0
1.20
1.21
mmol/l
0.97
119
840
36
154
2.56
5.72
8.7
9.2
23.21
24.97
mmol/l
3.38
36
154
16
45
3.73
5.13
2.3
1.6
—
—
—
0
0
30
141
2.28
3.90
2.6
2.6
76.36
70.08
ml/min/173m2
0.32
11
63
7
8
8.96
3.79
4.9
3.9
60.29
228.37
nmol/l
—
7
8
25
114
2.32
3.48
11.7
14.5
0.54
0.66
%
0.79
25
114
49
289
1.86
3.48
2.1
2.2
29.05
29.43
s
0.28
49
282
20
414
0.44
3.24
1.4
1.3
0.99
5.83
u/ml
—
7
159
82
583
1.60
2.94
3.0
2.9
0.74
0.36
e6/l
0.32
70
407
28
144
2.06
2.94
3.8
4.3
108.70
74.54
ng/l
0.33
23
131
11
35
3.24
2.68
3.8
3.1
4.67
5.13
kpa
1.18
11
35
10
30
3.43
2.63
1.8
2.8
15.91
16.16
%
—
10
30
7
15
4.77
2.61
1.0
1.7
—
—
—
0
0
12
42
2.95
2.58
1.9
1.5
—
—
—
0
0
147
1709
0.67
2.53
3.2
3.6
—
—
—
0
0
19
89
2.23
2.52
1.4
1.3
—
—
—
0
0
9
28
3.29
2.33
1.1
1.0
—
—
—
0
0
80
593
1.51
2.32
4.1
3.6
0.00
0.01
estimate
0.80
26
221
6
13
4.70
2.28
1.5
1.1
—
—
—
0
0
16
73
2.27
2.26
5.8
5.5
1.24
1.29
mg/l
0.21
16
65
13
54
2.48
2.23
1.8
1.5
—
—
—
0
0
5
9
5.64
2.22
2.0
1.4
—
—
—
0
0
5
9
5.64
2.22
2.0
1.4
—
—
—
0
0
121
982
1.45
2.19
3.1
2.8
—
—
estimate
—
0
0
5
10
5.08
2.08
2.2
1.5
—
—
—
0
0
12
50
2.47
2.06
1.5
1.2
—
—
—
0
0
39
251
1.65
2.05
12.7
8.1
105.33
104.59
mmol/l
0.39
39
251
90
698
1.45
2.05
2.9
3.1
20.32
22.67
ng/l
0.20
58
418
13
57
2.35
2.01
1.9
2.3
25.70
24.51
mmol/l
0.45
13
57
68
504
1.48
1.94
2.2
2.4
—
—
—
0
0
7
22
3.24
1.89
1.6
1.8
0.50
0.58
e9/l
—
7
22
29
450
0.60
1.85
1.3
1.3
26.00
26.90
iu/ml
—
7
138
129
1085
1.39
1.80
7.3
6.5
10.80
12.00
umol/l
0.57
124
1037
29
444
0.61
1.75
2.0
2.2
—
—
—
0
0
32
473
0.63
1.66
2.1
2.3
—
—
—
0
0
81
639
1.39
1.63
2.9
2.6
55.30
62.40
u/l
0.40
76
603
22
129
1.77
1.63
1.7
1.6
—
—
—
0
0
5
14
3.62
1.62
1.6
1.5
—
—
—
0
0
8
32
2.55
1.61
1.9
1.6
—
—
—
0
0
8
32
2.55
1.61
1.9
1.4
—
—
—
0
0
10
43
2.38
1.60
1.7
1.6
—
—
—
0
0
30
196
1.60
1.51
5.3
4.1
1.68
1.92
mmol/l
0.16
23
164
84
676
1.36
1.48
3.2
3.4
2.35
2.36
mmol/l
0.33
76
630
102
846
1.34
1.48
5.3
5.0
35.34
36.87
g/l
1.72
95
807
28
182
1.61
1.45
4.4
3.3
—
—
—
0
0
35
240
1.53
1.45
1.8
1.8
—
—
—
0
0
45
326
1.46
1.44
2.8
2.7
4.66
2.33
e6/l
0.95
22
138
176
1590
1.35
1.39
8.2
7.7
76.65
77.73
u/l
0.10
168
1508
49
364
1.43
1.38
2.8
2.5
1.30
0.68
e6/l
0.40
25
174
132
1149
1.31
1.33
4.0
3.4
0.03
0.00
estimate
0.40
31
230
14
77
1.87
1.28
1.8
1.4
—
—
—
0
0
26
172
1.57
1.26
2.0
4.1
2.48
35.27
ug/l
0.68
18
134
22
331
0.63
1.24
1.9
1.9
3.66
3.52
ratio
0.32
14
258
6
26
2.34
1.19
1.7
1.5
—
—
—
0
0
132
1162
1.28
1.18
4.0
3.4
0.00
0.00
estimate
-0.00
29
233
29
201
1.50
1.16
7.0
6.2
—
—
—
0
0
16
253
0.61
1.12
1.6
1.8
3.63
3.49
mmol/l
—
8
179
132
1169
1.27
1.09
4.0
3.5
0.00
0.00
estimate
-0.00
31
218
42
317
1.39
1.09
1.9
2.0
—
—
—
0
0
19
122
1.60
1.06
3.5
6.0
1.80
1.26
mmol/l
0.26
12
97
32
232
1.43
1.04
1.8
1.9
—
—
—
0
0
12
68
1.80
1.02
1.2
1.4
515.67
445.37
mg/l
0.25
12
63
12
68
1.80
1.02
1.8
1.5
—
—
—
0
0
14
85
1.68
0.96
1.4
1.2
—
—
—
0
0
61
498
1.30
0.95
1.8
1.8
0.70
0.95
mg/l
0.55
46
391
7
37
1.92
0.95
1.7
1.2
313.86
367.85
mu/l
—
7
27
6
27
2.25
0.94
1.3
1.2
—
—
—
0
0
10
55
1.85
0.93
1.9
2.4
—
—
—
0
0
225
2153
1.41
0.92
20.8
14.7
139.27
139.72
mmol/l
1.78
220
2108
100
871
1.24
0.92
3.8
3.2
0.00
0.02
estimate
0.68
26
199
225
2155
1.40
0.89
20.7
14.8
3.94
3.94
mmol/l
0.06
220
2103
8
43
1.89
0.88
1.6
1.5
—
—
—
0
0
62
513
1.28
0.88
4.2
3.4
1.02
1.02
kg/l
0.46
38
327
11
64
1.75
0.87
1.8
1.5
—
—
—
0
0
13
80
1.66
0.86
1.2
1.1
—
5.73
—
0
12
0
27
0.00
0.78
0.0
1.1
—
—
—
0
0
21
150
1.44
0.76
2.3
2.2
0.42
0.15
e6/l
0.56
21
141
7
38
1.87
0.74
2.3
1.4
—
—
—
0
0
46
377
1.27
0.71
3.5
3.4
476.00
374.89
ng/l
0.09
28
248
189
1983
0.81
0.69
3.8
3.8
1.19
1.25
mmol/l
0.60
171
1868
5
29
1.74
0.64
1.2
1.3
—
—
—
0
0
5
30
1.68
0.61
1.4
1.6
—
—
—
0
0
139
1291
1.17
0.58
10.4
9.9
4.42
3.98
e9/l
1.39
121
1117
202
2096
0.82
0.58
4.4
4.4
1.48
1.46
mmol/l
0.28
186
1984
5
87
0.57
0.57
1.8
1.5
1.10
1.17
g/l
—
5
81
49
572
0.82
0.57
3.3
4.1
4.02
8.76
mg/mmol
1.24
36
359
25
195
1.31
0.57
3.1
4.0
209.44
236.43
u/l
0.81
25
188
6
37
1.64
0.56
1.2
1.1
—
—
—
0
0
6
37
1.64
0.56
2.8
2.9
17.93
6.39
pmol/l
—
6
37
9
60
1.52
0.55
1.1
1.5
—
—
—
0
0
107
979
1.16
0.53
2.6
2.6
73.17
74.16
nmol/l
0.15
101
906
6
39
1.55
0.53
1.7
3.1
11.33
37.79
u/ml
—
6
39
58
657
0.85
0.49
1.5
1.4
1.22
1.93
u/ml
0.37
18
173
8
118
0.67
0.47
2.8
2.0
—
—
—
0
0
40
341
1.21
0.45
4.6
3.9
26.48
21.64
%
1.59
23
135
206
2119
0.85
0.41
5.1
5.0
2.83
2.78
mmol/l
0.34
191
2007
0
15
0.00
0.41
0.0
1.1
—
9.80
—
0
15
0
16
0.00
0.41
0.0
1.0
—
1583.88
—
0
16
56
624
0.87
0.38
1.5
1.7
—
—
—
0
0
9
67
1.36
0.38
1.7
2.1
137.37
199.52
ug/l
—
9
59
14
180
0.76
0.38
1.9
1.3
141.93
118.66
u/ml
—
8
73
5
37
1.36
0.37
1.2
1.2
—
—
—
0
0
198
2037
0.87
0.36
5.9
5.1
1.82
1.83
mu/l
0.01
184
1919
205
2104
0.86
0.36
4.5
4.5
4.73
4.68
mmol/l
0.29
191
2003
12
156
0.76
0.35
1.1
1.1
—
—
—
0
0
41
360
1.17
0.35
1.7
1.7
368.03
445.26
pmol/l
1.92
30
322
6
44
1.37
0.34
2.0
1.4
—
—
—
0
0
6
46
1.31
0.33
1.5
1.9
—
—
—
0
0
18
146
1.25
0.33
1.8
1.4
—
—
—
0
0
240
2428
0.78
0.30
25.8
19.9
4.65
4.57
e12/l
1.34
233
2384
24
279
0.85
0.28
2.0
2.3
—
—
—
0
0
59
541
1.12
0.28
1.5
1.6
15.67
21.76
nmol/l
3.62
53
473
216
2199
0.88
0.26
16.4
13.3
26.32
22.45
mg/l
0.73
179
1714
240
2425
0.80
0.25
25.8
20.0
261.78
256.18
e9/l
0.72
233
2388
6
85
0.70
0.24
1.3
1.7
—
—
—
0
0
5
40
1.25
0.22
1.2
1.3
—
—
—
0
0
5
40
1.25
0.22
1.2
1.3
—
—
—
0
0
5
40
1.25
0.22
1.0
1.3
7.66
22.20
u/l
—
5
33
13
156
0.82
0.22
1.2
1.3
—
31.58
—
0
12
5
42
1.19
0.21
1.0
1.1
—
—
—
0
0
8
102
0.78
0.21
1.1
1.1
1.61
1.56
g/l
—
8
102
8
104
0.76
0.21
1.4
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
8.65
—
0
11
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
2.4
—
3.09
—
0
5
0
14
0.00
0.20
0.0
1.2
—
206.82
—
0
14
0
14
0.00
0.20
0.0
2.3
—
—
—
0
0
6
50
1.20
0.20
1.3
1.1
—
1.51
—
0
12
6
52
1.16
0.19
6.8
5.8
—
770.00
—
0
7
12
100
1.21
0.18
1.9
1.8
—
—
—
0
0
87
830
1.07
0.18
1.8
2.0
92.00
95.99
pmol/l
0.35
52
430
7
62
1.13
0.17
1.3
1.4
—
—
—
0
0
5
67
0.74
0.17
1.4
1.5
62.08
51.51
ug/l
—
5
67
12
101
1.20
0.17
6.9
2.8
0.50
0.64
%
2.14
12
101
16
140
1.15
0.15
3.3
1.5
0.35
0.29
mg/l
—
9
57
22
243
0.90
0.14
1.8
2.1
—
—
—
0
0
16
141
1.14
0.14
1.7
2.4
373.17
4333.41
u/l
—
6
54
18
161
1.13
0.13
1.4
1.5
—
—
—
0
0
228
2299
0.92
0.11
11.6
10.6
22.54
27.54
u/l
5.71
219
2247
163
1603
1.05
0.10
3.6
4.1
10.34
9.51
mm/h
0.29
152
1509
96
933
1.05
0.10
1.7
1.9
1.20
1.35
mmol/l
1.40
81
809
12
106
1.14
0.10
1.2
2.1
35.05
40.69
u/l
0.46
12
96
5
45
1.11
0.10
13.8
5.0
3.76
3.91
mmol/l
—
5
45
40
420
0.94
0.09
1.5
1.5
—
—
—
0
0
6
56
1.07
0.08
1.2
1.9
—
—
—
0
0
197
1949
1.05
0.08
4.4
5.3
35.67
38.07
mmol/mol
5.51
183
1863
6
75
0.80
0.07
2.8
1.9
—
—
—
0
0
8
74
1.08
0.07
1.0
1.1
—
16.86
—
0
12
9
87
1.04
0.07
1.4
1.5
—
—
—
0
0
68
662
1.04
0.06
2.7
2.8
0.00
0.01
estimate
0.50
25
190
9
105
0.85
0.06
1.2
1.1
0.76
0.90
g/l
—
9
105
28
267
1.05
0.05
1.9
1.6
1054.73
1179.39
nmol/l
0.34
22
202
231
2302
1.04
0.02
21.3
15.8
70.47
72.55
umol/l
0.33
231
2271
199
1999
0.98
0.02
4.2
4.3
5.51
5.76
mmol/l
4.69
183
1873
50
494
1.02
0.00
2.3
2.9
335.74
329.25
umol/l
0.12
43
446
25
248
1.01
0.00
3.2
2.6
0.85
0.66
ug/l
0.68
17
135
174
1742
1.00
0.00
5.1
4.2
14.89
14.63
pmol/l
0.75
163
1608
203
2033
0.99
0.00
17.0
12.0
95.10
89.99
ml/min/173m2
2.07
185
1835
22
216
1.02
0.00
3.1
4.2
33.47
31.83
%
0.30
17
143
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
50.92
—
0
6
6
66
0.91
-0.00
1.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.6
—
1.00
—
0
9
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
9.86
—
0
7
0
5
0.00
-0.00
0.0
2.6
—
43.60
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
6
66
0.91
-0.00
1.8
2.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
54.17
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
99.33
—
0
6
6
67
0.89
-0.00
1.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: Q17_NEUROFIBROMATOSIS_1 – Neurofibromatosis, type 1
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).